Early prediction of treatment efficacy in second-stage gambiense human african trypanosomiasis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 6, 2012, Pages

  Priotto, Gerardo ^a   Chappuis, François ^b   Bastard, Mathieu ^a   Flevaud, Laurence ^c   Etard, Jean François ^a,d  

^a EPICENTRE   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX;

ADOLESCENT; ADULT; AFRICAN TRYPANOSOMIASIS; ALGORITHM; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; AFRICA; CEREBROSPINAL FLUID; CYTOLOGY; DRUG MONITORING; EVALUATION; ISOLATION AND PURIFICATION; METHODOLOGY; PARASITOLOGY; PATHOGENICITY; TIME; TRYPANOSOMA;

ADOLESCENT; ADULT; AFRICA; CEREBROSPINAL FLUID; DRUG MONITORING; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN; YOUNG ADULT;

EID: 84863678945     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001662     Document Type: Article

References (14)

1. World Health Organization (1998) Control and surveillance of African trypanosomiasis. WHO Technical Report Series 881: 1-114.
2. World Health Organization (2007) Recommendations of the Informal Consultation on Issues for Clinical Product Development for Human African Trypanosomiasis;WHO/CDS/NTD/IDM/2007.1.
3. Robays J, Lefort A, Lutumba P, et al. (2007) Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo. Trop Med Int Health 12: 290-8.
4. Moore AC, (2005) Prospects for improving African trypanosomiasis chemotherapy. J Infect Dis 191: 1793-5.
5. Lejon V, Roger I, Mumba Ngoyi D, Menten J, Robays J, et al. (2008) Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin Inf Dis 47 (1): 15-22.
6. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2010) How to Shorten Patient Follow-Up after Treatment for Trypanosoma brucei gambiense Sleeping Sickness. J Infect Dis Jan 4. PMID: 20047500.
7. Mumba Ngoyi D, Lejon V, N'Siesi FX, Boelaert M, Büscher P, (2009) Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis. Trop Med Int Health Apr;14 (4): 438-44 Epub 2009 Feb 17.
8. Simel DL, Samsa GP, Matchar DB, (1991) Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 44 (8): 763-70.
9. Deeks JJ, Altman DG, (2004) Diagnostic tests 4: likelihood ratios. BMJ 329 (7458): 168-9.
10. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet DOI:10.1016/S0140-6736(09)61117-X.
11. Lutje V, Seixas J, Kennedy A, (2010) Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database of Systematic Reviews 2010:8: CD006201 DOI:10.1002/14651858.CD006201.pub2.
12. Jaeschke R, Guyatt GH, Sackett DL, (1994) Users' guides to the medical literature. III. How to use an article about a diagnostic test. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271: 703-07.
13. Teasdale G, Jennett B, (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 304 (7872): 81-4 doi:10.1016/S0140-6736(74)91639-0.
14. Mor V, Laliberte L, Morris JN, Wiemann M, (1984) The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 53: 2002-7.